P2Y6受体作为基本高血压的潜在基石
Nuria Daghbouche-Rubio1, Inés Álvarez-Miguel1, Victor Alejandro Flores2
1Departamento de Bioquímica y Biología Molecular y Fisiología e Instituto de Biología y Genética Molecular (IBGM), Universidad de Valladolid y Consejo Superior de Investigaciones Científicas (CSIC), Valladolid, 47003, Spain.
Function (Oxford, England)
|September 25, 2024
概括
基本高血压涉及不清楚的机制. 这项研究表明,增加P2Y6受体 (P2ry6) 和血管新生素II受体 (Agtr1) 合增强了高血压中的血管反应性,这表明P2ry6是潜在的治疗标.
科学领域:
- 心血管研究研究心血管研究
- 分子药理学分子药理学
- 高血压病理生理学 高血压病理生理学
背景情况:
- 基本高血压 (HT) 是一种广泛的心血管疾病,其机制尚不清楚.
- 纯能P2Y6受体 (P2ry6) 涉及心血管功能和血管激素II (AgtII) 作用.
研究的目的:
- 调查假设,P2ry6和AgtII受体之间的功能合有助于改变HT的血管反应性.
- 探索P2ry6在高血压表型中的作用.
主要方法:
- 从正常和高血压小鼠中转录组对介质血管光滑肌细胞 (VSMCs) 的分析.
- 对P2Y受体激活和AgtII.II的血管反应的评估.
- 接近结合试验和超分辨率显微镜以确定受体定位.
主要成果:
- 在高血压小鼠中枢动脉中,P2ry6 mRNA的调节升高.
- 高血压小鼠对UTP和AgtII的血管收缩增强,而AgtII诱导的收缩对P2ry6调节器敏感.
- 在高血压小鼠中,Agtr1和P2ry6受体在细胞膜更接近.
结论:
- 增加P2ry6和Agtr1之间的功能合可能会导致高血压中血管反应的增强.
- 减少P2ry6表达与抗AgtII诱导的高血压相关.
- 阻止P2ry6是治疗高血压的潜在治疗策略.
相关概念视频
Antihypertensive Drugs: Angiotensin II Receptor Blockers
600
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
600
Hypertension and Regulation of Blood Pressure
1.9K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.9K
Antihypertensive Drugs: Action of β1 Blockers
314
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
314
Hypertension II: Pathophysiology
2
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
2
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
139
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
139


